



# Meet the Expert

## Prof. Zhou Wang

*Director of Urological Research, and UPMC Chair in Urological Research, University of Pittsburgh School of Medicine, USA*

Dr. Zhou Wang received his B.S. in Biology from the University of Science and Technology of China and his Ph.D. from the University of Pittsburgh. After post-doctoral training at the Carnegie Institution of Washington, Dr. Wang joined the Department of Urology at Northwestern University as an Assistant Professor in 1995 and was honored with the O'Connor Family Research Professorship in 2003. He was relocated to University of Pittsburgh in 2006. He has served as the Director of Urological Research since 2006, a Co-Leader of the Prostate Cancer Program at University of Pittsburgh Cancer Institute (UPCI) from 2006 to 2013, and a Co-Leader of the Molecular and Cellular Cancer Biology Program at UPCI from 2014 to 2017. He is currently the Director of the NIDDK-supported O'Brien Urology Research Center at University of Pittsburgh. He was a recipient of Junior Faculty Research Award from the American Cancer Society, Edwin Beer Award from the New York Academy of Medicine, SBUR/Merck Young Investigator Award, Jie-Ping Wu Award from Chinese Urology Society, and a MERIT Award from the NIH/NIDDK. Dr. Wang currently holds the UPMC Chair in Urological Research.



## *Major Research Interests*

Dr. Wang's research interests are on mechanisms of androgen action in the prostate and two androgen-dependent diseases, prostate cancer and benign prostatic hyperplasia (BPH). His long-term goal is to identify novel targets for developing new approaches to treat and/or prevent prostate cancer and BPH. Specifically, his lab investigates EAF2/U19, a tumor suppressor regulated by androgens and frequently down-regulated in prostate cancer, the mechanism of androgen receptor nucleocytoplasmic trafficking, the potential to improve intermittent androgen deprivation therapy (IADT) by using short off-cycles coupled with 5 $\alpha$ -reductase inhibition, and the role of inflammation and luminal epithelial layer permeability in BPH pathogenesis.

Dr. Zhou Wang is a member of the American Association of Cancer Research (AACR), the Endocrine Society, American Urological Association (AUA), Chinese Biological Investigators Society (CBIS), and Society for Basic Urologic Research (SBUR). He also served as Treasurer (2003–2007) and President (2011–2012) of SBUR. Dr. Zhou Wang is a reviewer board member for *Endocrinology*, *Prostate*, *Scientific Reports*, *Journal of Cancer Metastasis and Treatment*, *Cell & Bioscience*, and *Asian Journal of Andrology*. He also serves as Associate Editor-in-Chief for *American Journal of Clinical and Experimental Urology* (AJCEU).

## *Relation to Asian Journal of Andrology*

The *Asian Journal of Andrology* (AJA) publishes a lot of high quality original and review articles in andrology and related research areas. Many of my colleagues publish their work in AJA. The quality of the manuscripts in AJA has increased steadily, under the leadership of Chief Editor, with strong support from editorial staff. I have no doubt that AJA will continue to provide outstanding services to the field of andrology and related research. It is my honor and pleasure to serve on the editorial board of AJA.